Anti-CTLA-4 Human Monoclonal Antibody CP-675,206 in Patients With Advanced Hepatocellular Carcinoma

Inclusion Criteria: * Unequivocal diagnosis of HCC * unresectable disease not amenable to locoregional treatment. * a 4-week washout period after sorafenib or any other systemic agent * a 2-month washout period after internal or external radiation * HCV chronic infection * Child-Pugh stage A or B * Measurable disease according to RECIST criteria * ECOG \< 2 * expected survival \> 3 months * Adequate liver, renal and blood functions * ability to sign informed consent Exclusion Criteria: * previous treatment with an anti-CTL-4 agent * serious infections or disease compromising general health status * autoimmune disease that requires therapy * treatment with immunosuppressors * treatment with investigational agents * other neoplasms except skin and bladder superficial tumors * pregnancy or lactation * SNC metastasis * HIV infection * relevant heart disease (NYHA class III or IV)